ReviewJournal of translational medicine2024
Understanding the matrix: collagen modifications in tumors and their implications for immunotherapy.
Review in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 33 citations in OpenAlex.
- Enzyme-mediated remodeling of the extracellular matrix and glycocalyx to enhance immunotherapy in solid tumors.Bioengineering & translational medicine · 2026Review
- A Locally Injectable, pH/ROS-Responsive Hydrogel Platform for Combination Therapy of Cervical Cancer with Anti-Fibrotic and Chemotherapeutic Agents.Pharmaceutics · 2026Article
- Machine Learning-Assisted SHG Morphometry Reveals Distinct Collagen Microarchitectures of Trabecular Bone and Fibrosis in Bone Marrow Biopsies.International journal of molecular sciences · 2026Article
- Iron-endoplasmic reticulum-extracellular matrix axis regulates cancer cell invasion.bioRxiv : the preprint server for biology · 2026Article
- Collagen remodeling in breast cancer progression: from molecular mechanisms to diagnostic and therapeutic opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Structural architecture of collagen and collagen-fibronectin networks is associated with the invasive behavior of liver cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Tumor microenvironment and mechanotransduction pathways: Novel targets and new directions for cancer therapy.Mechanobiology in medicine · 2026Review
- Advances in near-infrared fluorescent probes for the tumor microenvironment.Journal of translational medicine · 2026Review
- Ablation-induced collagen exposure enables dual-modal nuclear imaging-guided local radionuclide therapy.Journal of nanobiotechnology · 2026Article
- The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer.Pharmaceutics · 2026Review
- Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8The American journal of pathology · 2026Article
- Features of the spatial organization and qualitative composition of the collagen matrix in prostate cancer.Journal of molecular histology · 2026Article
- The tumor immune microenvironment of thyroid cancer and colorectal cancer: cellular crosstalk and therapeutic implications.Frontiers in immunology · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer.Frontiers in oncology · 2026Review
- A prognostic gene signature derived from aging-related genes predicts survival, immune landscape and therapy response in glioma.Molecular and clinical oncology · 2026Article
- Matrix Metalloproteinase Inhibition in Melanoma.Experimental dermatology · 2026Review
- Targeting Collagens and LOX Through Plant-Derived MicroRNAs (XenomiRs).Methods in molecular biology (Clifton, N.J.) · 2026Article
- Preventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy.Science (New York, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Tumors are highly complex and heterogenous ecosystems where malignant cells interact with healthy cells and the surrounding extracellular matrix (ECM). Solid tumors contain large ECM deposits that can constitute up to 60% of the tumor mass. This supports the survival and growth of cancerous cells and plays a critical role in the response to immune therapy. There is untapped potential in targeting the ECM and cell-ECM interactions to improve existing immune therapy and explore novel therapeutic strategies. The most abundant proteins in the ECM are the collagen family. There are 28 different collagen subtypes that can undergo several post-translational modifications (PTMs), which alter both their structure and functionality. Here, we review current knowledge on tumor collagen composition and the consequences of collagen PTMs affecting receptor binding, cell migration and tumor stiffness. Furthermore, we discuss how these alterations impact tumor immune responses and how collagen could be targeted to treat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.